![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » BIOVAIL DOUBLES PROFIT, FORECASTS GROWTH
BIOVAIL DOUBLES PROFIT, FORECASTS GROWTH
March 23, 2006
Biovail Corp., whose fourth-quarter net income more than doubled, said Thursday it expects earnings growth of about 25 per cent this year, excluding charges. The drug developer expects to earn between $2.30 to $2.40 (U.S.), without charges. At the mid-point, that represents growth of about 25 per cent over 2005.
The Globe and Mail (http://www.theglobeandmail.com/servlet/story/RTGAM.20060323.wbiovail0323/BNStory/Business/home)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct